夏驭龙,周菁,蒋捷,霍东坡,王梓凝,谢秋芬,霍勇

• 1:北京大学第一医院心内科北京大学第一医院心血管疾病研究所

摘要(Abstract)：

目的描述单中心心房颤动(房颤)射频消融术后患者长期抗凝治疗的现状,探讨决定抗凝治疗策略的影响因素。方法选取2012年1月至2015年8月就诊于北京大学第一医院因房颤行射频消融治疗并于门诊随访的患者144例,收集并描述患者手术前基线资料、随访期间口服抗凝药物(OAC)使用情况及血栓栓塞和大出血事件的发生情况。根据射频消融3个月后是否中断抗凝治疗将患者分为两组,采用二元logistic回归分析射频消融术后患者长期抗凝治疗决策的影响因素。结果 144例房颤患者共行158次射频消融术,中位随访时间为17.5(12.0,29.8)个月。根据基线CHA2DS2-VASc评分,血栓栓塞高危患者共92例(63.9%)。1次射频消融术后12个月内房颤复发共53例(36.8%)。随访过程中,共140例(97.2%)患者按计划抗凝治疗至术后3个月,4例(2.8%)患者提前终止抗凝治疗。按计划抗凝治疗至术后3个月的140例患者中,CHADS2≥2分的46例患者中有17例(37.0%)、CHA2DS2-VASc≥2分的89例患者中有32例(36.0%)患者持续OAC;射频消融3个月后,共104例(74.3%)患者中断OAC,其中34例(32.7%)术后12个月内房颤复发,复发患者中有17例重新开始OAC。多因素二元logistic回归分析显示,术后12个月内房颤复发是影响是否持续抗凝的独立危险因素(OR 2.88,95%CI 1.22~6.79,P=0.016)。在校正了CHA2DS2-VASc评分后发现,术后12个月内房颤复发仍是影响是否持续抗凝的独立危险因素(OR 2.88,95%CI 1.21~6.81,P=0.016)。血栓栓塞事件共发生4例(2.8%),均发生于停用OAC后,根据术前血栓栓塞评分,4例患者CHA2DS2-VASc≥2分,仅2例患者CHADS2≥2分;其中3例患者术后12个月内无房颤复发。大出血事件共发生2例(1.4%),均发生于持续服用OAC过程中。结论射频消融术后12个月内房颤复发是除CHA2DS2-VASc外决定患者长期抗凝治疗的主要因素。

关键词(KeyWords)： 心房颤动;射频消融;危险分层;血栓栓塞;大出血;口服抗凝

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 夏驭龙,周菁,蒋捷,霍东坡,王梓凝,谢秋芬,霍勇

参考文献(References)：

• [1]Go AS,Hylek EM,Phillips KA,et al.Prevalence of diagnosed atrial fibrillation in adults:national implications for rhythm management and stroke prevention:the An Ticoagulation and Risk Factors in Atrial Fibrillation(ATRIA)Study.JAMA,2001,285(18):2370-2375.
• [2]Benjamin EJ,Wolf PA,D'Agostino RB,et al.Impact of atrial fibrillation on the risk of death:the Framingham Heart Study.Circulation,1998,98(10):946-952.
• [3]European Heart Rhythm A,European Association for CardioThoracic S,Camm AJ,et al.Guidelines for the management of atrial fibrillation:the task force for the management of atrial fibrillation of the European Society of Cardiology(ESC).Eur Heart J,2010,31(19):2369-2429.
• [4]Lip GY,Nieuwlaat R,Pisters R,et al.Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach:the euro heart survey on atrial fibrillation.Chest,2010,137(2):263-272.
• [5]Gage BF,Waterman AD,Shannon W,et al.Validation of clinical classification schemes for predicting stroke:results from the National Registry of Atrial Fibrillation.JAMA,2001,285(22):2864-2870.
• [6]Olesen JB,Lip GY,Hansen PR,et al.Bleeding risk in'real world'patients with atrial fibrillation:comparison of two established bleeding prediction schemes in a nationwide cohort.J Thromb Haemost,2011,9(8):1460-1467.
• [7]Haissaguerre M,Jais P,Shah DC,et al.Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci.Circulation,2000,101(12):1409-1417.
• [8]黄从新,张澍,黄德嘉,等.心房颤动:目前的认识和治疗建议-2015.中华心律失常学杂志,2015,19(5):321-383.
• [9]Calkins H,Kuck KH,Cappato R,et al.2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation:recommendations for patient selection,procedural techniques,patient management and followup,definitions,endpoints,and research trial design.Europace,2012,14(4):528-606.
• [10]Oral H,Chugh A,Ozaydin M,et al.Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation.Circulation,2006,114(8):759-765.
• [11]中华医学会神经病学分会脑血管病学组.中国急性缺血性卒中诊治指南2014.中华神经科杂志,2015,48(4):246-257.
• [12]Lin YJ,Chao TF,Tsao HM,et al.Successful catheter ablation reduces the risk of cardiovascular events in atrial fibrillation patients with CHA2DS2-VASc risk score of 1 and higher.Europace,2013,15(5):676-684.
• [13]Connolly SJ,Ezekowitz MD,Yusuf S,et al.Dabigatran versus warfarin in patients with atrial fibrillation.N Engl J Med,2009,361(12):1139-1151.
• [14]Ogilvie IM,Newton N,Welner SA,et al.Underuse of oral anticoagulants in atrial fibrillation:a systematic review.Am J Med,2010,123(7):638-645.
• [15]Themistoclakis S,Corrado A,Marchlinski FE,et al.The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation.J Am Coll Cardiol,2010,55(8):735-743.
• [16]Karasoy D,Gislason GH,Hansen J,et al.Oral anticoagulation therapy after radiofrequency ablation of atrial fibrillation and the risk of thromboembolism and serious bleeding:long-term followup in nationwide cohort of Denmark.Eur Heart J,2015,36(5):307-314.
• [17]Verma A,Champagne J,Sapp J,et al.Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation(DISCERN AF):a prospective,multicenter study.JAMA Intern Med,2013,173(2):149-156.
• [18]Schreiber D,Rostock T,Frohlich M,et al.Five-year follow-up after catheter ablation of persistent atrial fibrillation using the stepwise approach and prognostic factors for success.Circ Arrhythm Electrophysiol,2015,8(2):308-317.
• [19]Chao TF,Lin YJ,Tsao HM,et al.CHADS(2)and CHA(2)DS(2)-VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation.J Am Coll Cardiol,2011,58(23):2380-2385.
• [20]Jacobs V,May HT,Bair TL,et al.The impact of risk score(CHADS2 versus CHA2DS2-VASc)on long-term outcomes after atrial fibrillation ablation.Heart Rhythm,2015,12(4):681-686.